<DOC>
	<DOCNO>NCT02807103</DOCNO>
	<brief_summary>Phase III , comparative , multicenter , randomize , control , double-blind superiority research , compare rituximab-based regimen conventional therapeutic strategy induction remission patient eosinophilic granulomatosis polyangiitis ( EGPA ) . Patients newly diagnose relapse EGPA randomize 1:1 ratio receive : - Experimental therapeutic strategy base use rituximab ( experimental group ) - Conventional therapeutic strategy base Five-Factor Score ( FFS ) -assessed disease severity ( comparative group )</brief_summary>
	<brief_title>Rituximab Eosinophilic Granulomatosis With Polyangiitis</brief_title>
	<detailed_description>Systemic vasculitides inflammatory disease blood vessel , among anti-neutrophil cytoplasmic antibody ( ANCA ) -associated vasculitides ( AAV ) often severe life-threatening manifestation complication . AAV include granulomatosis polyangiitis ( GPA ) , microscopic polyangiitis ( MPA ) eosinophilic granulomatosis polyangiitis ( EGPA , formerly Churg-Strauss syndrome ) . Cytotoxic drug glucocorticoid standard care remission induction nearly five decade . This regimen improved outcome severe AAV death strong likelihood disease control temporary remission . However , remission obtain patient combination drug , patient experience disease flare require repeat treatment associate significant morbidity mortality . In 2 prospective control trial , rituximab , anti-CD20 monoclonal antibody , show non inferior cyclophosphamide induce remission acceptable safety profile patient systemic GPA MPA . However , patient EGPA include trial rituximab evaluate prospectively induce remission disease pathogenesis complex restrict ANCA responsibility . In patient EGPA , overall survival good treatment stratify accord prognostic factor ( Five Factor Score ) long-term outcome good since relapse occur 40 % patient , lead high cumulative morbidity damage . In small retrospective study , rituximab seem promise remission-induction agent patient EGPA , independently ANCA status . The trial detail first prospective trial evaluate rituximab induction-remission treatment EGPA .</detailed_description>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Churg-Strauss Syndrome</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients diagnosis EGPA independently ANCA status , Patient age 18 year old , Patients newlydiagnosed disease relapse disease time screening , active disease define Birmingham Vasculitis Activity Score ( BVAS ) ≥3 , Patients within first 21 day follow initiation/increase corticosteroid dose ≤ 1 mg/kg/day , Patient able give write informed consent prior participation study . Patients GPA , MPA , vasculitides , define ACR criterion and/or Chapel Hill Consensus Conference , Patients vasculitis remission disease define BVAS &lt; 3 , Patients severe cardiac failure define class IV New York Heart Assocation Patients acute infection chronic active infection ( include HIV , HBV HCV ) , Patients active cancer recent cancer ( &lt; 5 year ) , except basocellular carcinoma prostatic cancer low activity control hormonal treatment , Pregnant woman lactation . Patients childbearing potential reliable contraception 12 month duration study , Patients EGPA already treat rituximab within previous 12 month , Patients hypersensitivity monoclonal antibody biologic agent , Patients contraindication use rituximab , cyclophosphamide , mesna azathioprine , Patients uncontrolled disease , include drug alcohol abuse , severe psychiatric disease , could interfere participation trial accord protocol , Patients include investigational therapeutic study within previous 3 month , Patients suspect observant propose treatment , Patients white blood cell count ≤4,000/mm3 , Patients platelet count ≤100,000/mm3 , Patients ALT AST level great 3 time upper limit normal attribute underlying EGPA disease , Patients unable give write informed consent prior participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>remission induction</keyword>
	<keyword>eosinophilic granulomatosis polyangiitis</keyword>
</DOC>